0.05% Voclosporin Ophthalmic Solution (VOS)

Phase 3

Aurinia Pharmaceuticals Inc. (AUPH)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Dry Eye Syndrome

HRTIS.HEcis-UCA ophthalmic solution 1.0%

Phase 2

View Full Landscape

Drug Information

Target Indication

Dry Eye Syndrome

Clinical Trial

NCT04147650

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Luveniq

treatment of non-infectious uveitis

View on EMA

EMA9/15/2022

Lupkynis

Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AUPH

Aurinia Pharmaceuticals Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

VoclosporinPhase 3

Lupus Nephritis

CiclosporinPhase 3

Psoriasis

Voclosporin High DosePhase 2

Lupus Nephritis

Voclosporin Ophthalmic SolutionPhase 2

Dry Eye

AritinerceptPhase 2

Myasthenia Gravis, Generalized

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts